More News! 14 Oct 2018 Living Instruments: Making Music with Yeast, Moss and Paramecia These instruments are alive. Yeast, moss and paramecia are behind the unique sounds of Living Instruments, which will be performing a concert in Zurich on October 21st. Instead of strings or windpipes, the sounds of these instruments are generated by living beings. The sound of the ‘yeast organ’ is triggered by the bubbles produced by […] October 14, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 12 Oct 2018 European Commission Updates Strategy to Energize Europe’s Bioeconomy In challenging times of climate change and a scarcity of resources, the European Commission has released a new strategy to boost activity and investment in companies contributing to the bioeconomy. As one of the key economies that signed the Paris Agreement in 2015, the EU aims to cut greenhouse gas emissions by at least 40% […] October 12, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 12 Oct 2018 This Biotech is the First to Work on Antivirals for Farm Livestock While in Leuven, Belgium, for last week’s Biotech of the Week, we decided to go to the vet. ViroVet is a company aiming to improve viral disease control in livestock, which is a huge sector of global agriculture. Mission: To develop novel antivirals and vaccines for farm livestock. This would give farmers more tools for […] October 12, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2018 Rechargeable Dentures Could Prevent Mouth Infections As well as helping you chew your hamburger, dentures could one day fight oral fungal infections, suggest researchers from Manchester Metropolitan University, UK. The population is getting older. In fact, it is predicted that almost half of Europe will be over 50 years old in the year 2050. Assuming that trends stay the same, this […] October 11, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2018 Cancer Immunotherapy Phase I on Hold After Patient Death The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […] October 10, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 10 Oct 2018 This Test Can Detect Four Drugs With Just a Fingerprint The British company Intelligent Fingerprinting has shown that its non-invasive fingerprint drug test can yield results comparable to blood tests in just 10 minutes. The technology, developed at the University of East Anglia, can detect extremely low amounts of amphetamines, cannabis, cocaine and opiate drugs from the sweat of a single fingerprint. The sample is […] October 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 10 Oct 2018 How to Make Industrial Biotech Pay Making enough money to survive long enough to get a product to market can be tough for any biotech, but even more so for companies operating in the industrial space, where it can be less easy to predict development time and potential financial returns. At our recent Refresh event in Paris, Emmanuel Petiot, CEO of […] October 10, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2018 Slow-Release Drug Biotech IPO Raises €30M The French biotech MedinCell, an injectable slow-release drug specialist, has received a shot of success as its IPO raises €30M in the Euronext stock exchange in Paris. MedinCell is hoping to improve patient compliance with medication regimes by injecting them with a drug-infused gel. Patient compliance with taking medication can be as low as 30% […] October 9, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2018 Hormone Therapy for Inherited Hormonal Disorder Fails at Phase III A European Phase III trial has become a major stress for British biotech Diurnal. Its specially designed hormone therapy was no better than conventional therapies in treating an inherited hormonal disorder. Congenital adrenal hyperplasia is a rare genetic condition where patients lack crucial enzymes for making hormones. The most common form lacks 21-hydroxylase, the enzyme […] October 9, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 Oct 2018 How to Capitalize on Opportunities in Underserved Disease Areas Developing treatments for underserved diseases can be surprisingly profitable for biotechs, we asked the experts to tell us more about how best to exploit these areas. We hear a lot about cancer therapies or drugs to target heart disease in the press, but overall a lot less about treatments for more underserved areas. Often successful […] October 9, 2018 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 8 Oct 2018 Cannabinoid Drugs Company Raises $300M in Public Offering GW Pharmaceuticals, a British biotech developing cannabinoid drugs, is on a high after a successful $300M public offering on the Nasdaq Stock Market. The company announced the public offering swiftly after its lead cannabinoid drug, Epidiolex, made history by being the first cannabinoid drug to obtain approval from the FDA earlier this year. GW plans […] October 8, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email